Dr Amin Asfor

Postdoctoral Scientist

Molecular Biology, Molecular Virology, Vaccinology

Dr Amin Asfor is a Postdoctoral Research Scientist in the Picornavirus Molecular Biology group at The Pirbright Institute. Amin obtained his BVSc from Alexandria University, Egypt and PhD in Molecular Virology from the Royal Veterinary College, London University and Animal and Plant Health Agency (Weybridge), investigating the role of Viral glycoprotein E2 in the host range restriction of Pestiviruses. Amin joined The Pirbright Institute in 2009, since then he identified a novel antibody binding determinants on the capsid surface of foot-and-mouth disease virus (FMDV).

Dr Asfor's research interest includes: evolution of viral immune-escape using next generation sequences, identifying novel antigenic sites, and identifying novel conserved epitopes as candidate for cross-serotypes vaccines and developing pan serotypes diagnostic assays. He has published some of the findings in a peer reviewed journals and presented several research papers in several international conferences. His research projects are linked with different research groups in the UK e.g. Oxford University, Imperial College, London, Glasgow University and World reference Laboratory for vesicular disease at The Pirbright Institute, UK.

Amin has experience in supporting and guiding PhD students towards completion of their degrees and supervising placement students.

News
Publications

IBDV protein that dampens poultry immune response could inform vaccine development

Studies at Pirbright demonstrate two doses of Oxford University’s COVID-19 vaccine boosts immune response in pigs

Pirbright develops universal foot-and-mouth disease virus test

Pirbright innovation recognised at the BBSRC Innovator of the Year Awards

Pirbright scientists produce lab technique which reduces need for experimental chickens

Asfor A, Howe N, Grazioli S, Berryman S, Parekh K, Wilsden G, Ludi A, King D, Parida S, Brocchi E, Tuthill T (2020)

Detection of bovine antibodies against a conserved capsid epitope as the basis of a novel universal serological test for foot-and-mouth disease

Journal of Clinical Microbiology 58 (6)

Publisher’s version: https://doi.org/10.1128/JCM.01527-19

Dulwich K L, Asfor A, Gray A, Giotis E S, Skinner M A, Broadbent A J (2020)

The stronger downregulation of in vitro and in vivo innate antiviral responses by a very virulent strain of infectious bursal disease virus (IBDV), compared to a classical strain, is mediated, in part, by the VP4 protein

Frontiers in Cellular and Infection Microbiology 10 , 315

Publisher’s version: https://doi.org/10.3389/fcimb.2020.00315

Graham S P, McLean R K, Spencer A J, Belij-Rammerstorfer S, Wright D, Ulaszewska M, Edwards J C, Hayes J W P, Martini V, Thakur N, Conceicao C, Dietrich I, Shelton H, Waters R, Ludi A, Wilsden G, Browning C, Bialy D, Bhat S, Stevenson-Leggett P, Hollinghurst P, Gilbride C, Pulido D, Moffat K, Sharpe H, Allen E, Mioulet V, Chiu C, Newman J, Asfor A S, Burman A, Crossley S, Huo J, Owens R J, Carroll M, Hammond J A, Tchilian E, Bailey D, Charleston B, Gilbert S C, Tuthill T J, Lambe T (2020)

Evaluation of the immunogenicity of prime-boost vaccination with the replication-deficient viral vectored COVID-19 vaccine candidate ChAdOx1 nCoV-19

npj Vaccines 5 (1) , 69

Publisher’s version: https://doi.org/10.1038/s41541-020-00221-3

Dulwich K L, Asfor A S, Gray A G, Venugopal N, Broadbent A J (2018)

An ex vivo chicken primary bursal-cell culture model to study infectious bursal disease virus pathogenesis

Journal of Visualized Experiments 140 , e58489

Publisher’s version: https://doi.org/10.3791/58489

Mousnier A, Bell A S, Swieboda D P, Morales-Sanfrutos J, Pérez-Dorado I, Brannigan J A, Newman J, Ritzefeld M, Hutton J A, Guedán A, Asfor A S, Robinson S W, Hopkins-Navratilova I, Wilkinson A J, Johnston S L, Leatherbarrow R J, Tuthill T J, Solari R, Tate E W (2018)

Fragment-derived inhibitors of human N-myristoyltransferase block capsid assembly and replication of the common cold virus

Nature Chemistry 10 (6) , 599-606

Publisher’s version: https://doi.org/10.1038/s41557-018-0039-2

Shimmon G, Kotecha A, Ren J, Asfor A S, Newman J, Berryman S, Cottam E M, Gold S, Tuthill T J, King D P, Brocchi E, King A M Q, Owens R, Fry E E, Stuart D I, Burman A, Jackson T (2018)

Generation and characterisation of recombinant FMDV antibodies: Applications for advancing diagnostic and laboratory assays

PLoS ONE 13 (8) , e0201853

Publisher’s version: https://doi.org/10.1371/journal.pone.0201853

Groups

Birnaviruses

Dr Amin Asfor

IBDV protein that dampens poultry immune response could inform vaccine development

Studies at Pirbright demonstrate two doses of Oxford University’s COVID-19 vaccine boosts immune response in pigs

Pirbright develops universal foot-and-mouth disease virus test

Pirbright innovation recognised at the BBSRC Innovator of the Year Awards

Pirbright scientists produce lab technique which reduces need for experimental chickens

Detection of bovine antibodies against a conserved capsid epitope as the basis of a novel universal serological test for foot-and-mouth disease

The stronger downregulation of in vitro and in vivo innate antiviral responses by a very virulent strain of infectious bursal disease virus (IBDV), compared to a classical strain, is mediated, in part, by the VP4 protein

Evaluation of the immunogenicity of prime-boost vaccination with the replication-deficient viral vectored COVID-19 vaccine candidate ChAdOx1 nCoV-19

An ex vivo chicken primary bursal-cell culture model to study infectious bursal disease virus pathogenesis

Fragment-derived inhibitors of human N-myristoyltransferase block capsid assembly and replication of the common cold virus

Generation and characterisation of recombinant FMDV antibodies: Applications for advancing diagnostic and laboratory assays

Pages

Trim content

You are here

Groups

Dr Amin Asfor

Pages

Trim content